Industry ownership intelligence

Medical Devices insider conviction

Executive and director activity assessed across 83 companies for breadth, transaction quality, clustering, freshness, and directional conviction.

Market dashboardHealthcare sectorCompany signalsFiling ledgerData API
48/100

Balanced insider tape

90/100 confidence
Level
Industry
Evidence window
Latest 90 days
Named insiders
642
Latest evidence
7 Aug 2026

Capital positioning read

Balanced insider tape

Acquisition and disposal evidence is mixed after low-information compensation and derivative activity is separated out.

Wait for clearer clustering

Evidence in favour

  • 126 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 642 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 07 Aug 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction48Balanced insider tape
Confidence90Deep evidence
Controlled events489directional common-share events
Company breadth83represented companies
Acquisition value$26.8Mnormalized amount
Disposal value$270.7Mnormalized amount

Flow regime

Twelve-week filing pressure

Shows the cadence and balance of the full filing tape.

15825 May
30901 Jun
16008 Jun
15715 Jun
7922 Jun
11129 Jun
7006 Jul
4213 Jul
3420 Jul
8227 Jul
5303 Aug
010 Aug
AcquisitionsDisposalsScore 48 · Confidence 90

Relative positioning

Industry peer map

Current score with confidence.

Pharmaceutical RetailersConviction accumulation7216 confidence Medical DistributionAccumulation bias6667 confidence Drug Manufacturers - GeneralAccumulation bias5794 confidence BiotechnologyBalanced insider tape5291 confidence Medical DevicesBalanced insider tape4890 confidence Diagnostics & ResearchDistribution bias3895 confidence Medical Care FacilitiesDistribution bias3693 confidence Health Information ServicesDistribution bias3691 confidence Medical Instruments & SuppliesDistribution bias3691 confidence Drug Manufacturers - Specialty & GenericDistribution bias3594 confidence Healthcare PlansDistribution bias3492 confidence

Directional balance

Controlled event mix

25.8%acquisition
Acquisition events
126
Disposal events
363
Net value
-$243.9M

Evidence quality

What the filings represent

Common equity1021
Equity compensation301
Options and derivatives231
Other securities10

Decision makers

Role participation

Director886
Other executive252
CEO and chair145
Finance leadership115
Other or unspecified112
Large holder53

Quality controls

Evidence usability

Normalized values
34%
Priced common share
33%
Named insiders
642
Controlled events
489

Auditable evidence

Latest Medical Devices filings

Showing 1141 to 1170 of 1563.

ZBHZimmer Biomet Holdings Inc
YI, SANGGroup President, Asia Pacific
DisposalCommon equity
$66.1KDirectional evidence
CERSCerus Corporation
JAYARAMAN, VIVEK KChief Operating Officer
DisposalCommon equity
$50.0KDirectional evidence
SIBNSi-Bone Inc
DAVIS, TIMOTHY E JRDirector
DisposalCommon equity
$49.5KDirectional evidence
EWEdwards Lifesciences Corp
DAHL, ANDREW M.SVP, Corporate Controller
DisposalCommon equity
$48.9KDirectional evidence
IRTCiRhythm Technologies Inc
FREEMAN, SEAN CLINTONEVP, Strategy & Corp Devt
AcquisitionCommon equity
$26.4KDirectional evidence
RPIDRapid Micro Biosystems Inc
LOWENSTEIN, INESEDirector
AcquisitionCommon equity
$25.0KDirectional evidence
RPIDRapid Micro Biosystems Inc
MALLOY, KIRKDirector
AcquisitionCommon equity
$25.0KDirectional evidence
RPIDRapid Micro Biosystems Inc
PEI, MELINDA LITHERLANDDirector
AcquisitionCommon equity
$25.0KDirectional evidence
RPIDRapid Micro Biosystems Inc
SPIGNESI, ROBERT G. JR.Director, PRESIDENT AND CEO
AcquisitionCommon equity
$25.0KDirectional evidence
RPIDRapid Micro Biosystems Inc
WIRTJES, SEAN MCHIEF FINANCIAL OFFICER
AcquisitionCommon equity
$25.0KDirectional evidence
IRTCiRhythm Technologies Inc
BLACKFORD, QUENTIN S.Director, President and CEO
AcquisitionCommon equity
$17.2KDirectional evidence
IRTCiRhythm Technologies Inc
ROSENBAUM, MARC WADEChief Accounting Officer
AcquisitionCommon equity
$17.2KDirectional evidence
IRTCiRhythm Technologies Inc
PATTERSON, CHADCHIEF COMM & PRODUCT OFFICER
AcquisitionCommon equity
$17.1KDirectional evidence
RCELAvita Medical Ltd
O'TOOLE, DAVID DCFO
AcquisitionCommon equity
$15.3KDirectional evidence
RCELAvita Medical Ltd
VANCE, CARY GUYDirector, President and CEO
AcquisitionCommon equity
$15.3KDirectional evidence
IRTCiRhythm Technologies Inc
TURAKHIA, MINANGCHIEF MED/SCI OFCR EVP ADVTECH
AcquisitionCommon equity
$13.3KDirectional evidence
IRTCiRhythm Technologies Inc
SHRISHRIMAL, SUMIEVP, Chief Risk Officer
AcquisitionCommon equity
$12.9KDirectional evidence
SERASera Prognostics Inc
JACKSON, BENJAMINGeneral Counsel
AcquisitionCommon equity
$9.2KDirectional evidence
SERASera Prognostics Inc
ANDERSON, DYAARL LEE JR.Chief Commercial Officer
AcquisitionCommon equity
$5.8KDirectional evidence
BSXBoston Scientific Corp
MAHONEY, MICHAEL FDirector, Chairman, President & CEO
DisposalCommon equity
Not reportedContext evidence
DXCMDexCom Inc
ALTMAN, STEVEN RDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
ASHLEY, EUAN A.Director
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
AUGUSTINOS, NICHOLASDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
COLLINS, RICHARD ALEXANDERDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
DRISCOLL, RIMMADirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
FOLETTA, MARK GDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
GALA, RENEE DDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
HELLER, BRIDGETTE PDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
MALADY, KYLEDirector
AcquisitionCommon equity
Not reportedContext evidence
DXCMDexCom Inc
OSTERLOH, ALBERT FREDERICK IVDirector
AcquisitionCommon equity
Not reportedContext evidence

Group-level method

Breadth before headline value

Company breadth

A sector or industry score must be supported across companies. One very large filing cannot manufacture broad conviction.

Economic duplicates

Matching company, date, side, security class, share count, and value records are consolidated for the directional calculation.

Evidence hierarchy

Priced common-share activity determines direction. Compensation and derivative records are mapped separately so ownership mechanics remain visible.

Positioning use

The score identifies where insider alignment merits research or where disposal concentration needs review. Price, trend, valuation, and portfolio risk still decide positioning.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context